Universal Beteiligungs und Servicegesellschaft mbH Has $5.09 Million Holdings in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY)

Key Points

• Universal Beteiligungs und Servicegesellschaft mbH increased its stake in Harmony Biosciences by 63.1%, acquiring an additional 59,315 shares and bringing its total ownership to 153,326 shares.
• Research firms have recently provided mixed ratings for Harmony Biosciences, with Goldman Sachs giving a "neutral" rating and Oppenheimer issuing an "outperform" rating.
• Harmony Biosciences reported a net margin of 20.53% and revenue growth of 19.5% compared to the same quarter last year, with a recent EPS of $0.78.

Universal Beteiligungs und Servicegesellschaft mbH boosted its stake in shares of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY - Free Report) by 63.1% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 153,326 shares of the company's stock after buying an additional 59,315 shares during the period. Universal Beteiligungs und Servicegesellschaft mbH owned 0.27% of Harmony Biosciences worth $5,089,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds also recently bought and sold shares of the stock. Aurora Investment Counsel lifted its holdings in shares of Harmony Biosciences by 0.6% during the 1st quarter. Aurora Investment Counsel now owns 61,667 shares of the company's stock valued at $2,047,000 after purchasing an additional 374 shares during the last quarter. O Shaughnessy Asset Management LLC lifted its holdings in shares of Harmony Biosciences by 2.1% during the 4th quarter. O Shaughnessy Asset Management LLC now owns 20,450 shares of the company's stock valued at $704,000 after purchasing an additional 420 shares during the last quarter. Rhumbline Advisers lifted its holdings in shares of Harmony Biosciences by 0.4% during the 1st quarter. Rhumbline Advisers now owns 109,073 shares of the company's stock valued at $3,620,000 after purchasing an additional 485 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its holdings in shares of Harmony Biosciences by 1.1% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 62,331 shares of the company's stock valued at $2,145,000 after purchasing an additional 678 shares during the last quarter. Finally, Aviva PLC lifted its holdings in shares of Harmony Biosciences by 3.9% during the 4th quarter. Aviva PLC now owns 18,072 shares of the company's stock valued at $622,000 after purchasing an additional 686 shares during the last quarter. Hedge funds and other institutional investors own 86.23% of the company's stock.

Harmony Biosciences Trading Up 0.5%

Harmony Biosciences stock traded up $0.19 during trading on Thursday, hitting $35.67. The company had a trading volume of 119,782 shares, compared to its average volume of 662,805. Harmony Biosciences Holdings, Inc. has a 1-year low of $26.47 and a 1-year high of $41.61. The company has a current ratio of 3.67, a quick ratio of 3.63 and a debt-to-equity ratio of 0.22. The company's 50 day simple moving average is $34.07 and its 200-day simple moving average is $34.00. The stock has a market cap of $2.05 billion, a price-to-earnings ratio of 13.61, a price-to-earnings-growth ratio of 0.46 and a beta of 0.83.

Harmony Biosciences (NASDAQ:HRMY - Get Free Report) last posted its earnings results on Tuesday, May 6th. The company reported $0.78 earnings per share for the quarter, beating the consensus estimate of $0.59 by $0.19. The firm had revenue of $184.73 million during the quarter, compared to the consensus estimate of $184.26 million. Harmony Biosciences had a net margin of 20.53% and a return on equity of 24.32%. The firm's revenue for the quarter was up 19.5% on a year-over-year basis. During the same quarter last year, the firm earned $0.67 EPS. As a group, analysts expect that Harmony Biosciences Holdings, Inc. will post 2.43 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms recently issued reports on HRMY. Needham & Company LLC reissued a "buy" rating and issued a $49.00 target price on shares of Harmony Biosciences in a research report on Tuesday, May 6th. The Goldman Sachs Group began coverage on Harmony Biosciences in a research report on Thursday, July 10th. They issued a "neutral" rating and a $33.00 target price on the stock. UBS Group cut their target price on Harmony Biosciences from $55.00 to $48.00 and set a "buy" rating on the stock in a research report on Monday, April 28th. Cantor Fitzgerald raised Harmony Biosciences to a "strong-buy" rating in a research report on Tuesday, May 13th. Finally, HC Wainwright reissued a "buy" rating and issued a $70.00 target price on shares of Harmony Biosciences in a research report on Tuesday, April 8th. One investment analyst has rated the stock with a hold rating, eight have issued a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat, the stock presently has an average rating of "Buy" and a consensus target price of $51.00.

About Harmony Biosciences

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.